Princeton, NJ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financingProceeds will support comple

read more>>

Oslo, Norway -- Clavis Pharma (OSE: CLAVIS), the Norwegian cancer drug development company, announces that it has recruited the first patient into its pivotal Phase III study assessing its lead product elacytarabine in patients with late-stage acute myeloid leukemia (AMLElacytarabine is a novel, p

read more>>

Like most four-month-olds, Michaila Davidson loves to spin around in her saucer walker and play with each toy strewn around her; but in the confines of the stem cell wing of the Center for Cancer and Blood Disorders at Children's Medical Center, Dallas - the hospital that has been her home since S

read more>>

WASHINGTON -- The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of HematologyAML i

read more>>

LOS ANGELES -- J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One FoundationThe award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (AL

read more>>

Scott & White's Cancer Research Institute (CRI) is conducting a clinical trial that targets malignant T-cell lymphoma, a type of blood cancerLymphoma, which affects the white blood cells that normally protect against illness, is categorized either as B-cell or T-cell. About 85% of lymphomas ar

read more>>

Cynthia Vale only sees her 1-year-old son Isaac on the weekends. During the week, she spends her time at Texas Children’s Hospital in Houston, looking after her 3-year-old son Samuel, who was diagnosed with acute myelogenous leukemia in May“It’s hard,” said Vale, whose fami

read more>>

CAMBRIDGE, Mass. -- Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patientsHigh levels of Musashi 2 protein is associated with increase

read more>>

BERKELEY HEIGHTS, NJ -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug &ldq

read more>>

TARRYTOWN, N.Y. -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene(R) (histamine dihydrochlorideEpiCept is seeking approval for Ceplene, administered concomitant

read more>>